A case-control study of the risk factors for developing aspergillosis following cardiac transplant

被引:9
作者
Cook, Jennifer C. [1 ]
Cook, Abigail [2 ]
Tran, Richard H. [3 ]
Chang, Patricia P. [4 ]
Rodgers, Jo E. [5 ]
机构
[1] Duke Univ, Dept Pharm, Durham, NC USA
[2] Loyola Univ Hlth Syst, Loyola Med, Maywood, IL USA
[3] Pharmaceut Product Dev, Morrisville, NC USA
[4] Univ N Carolina, UNC Sch Med, Chapel Hill, NC USA
[5] Univ N Carolina, UNC Eshelman Sch Pharm Univ, Chapel Hill, NC USA
关键词
antifungal prophylaxis; heart transplant; invasive aspergillosis; INVASIVE FUNGAL-INFECTIONS; TARGETED ANTIFUNGAL PROPHYLAXIS; HEART-TRANSPLANTATION; RECIPIENTS; DIAGNOSIS; DISEASE;
D O I
10.1111/ctr.13367
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Invasive aspergillosis (IA) is a significant cause of morbidity and mortality following cardiac transplantation; however, data regarding the predictors of IA in this patient population are limited. Methods: We conducted a case-control study to identify the risk factors for IA in patients who underwent cardiac transplantation at a single center from 1986 to 2008 (Cohort 1) and 2009 to 2015 (Cohort 2). Cases of IA were matched to two controls from the same year of transplantation, arid data were collected from the date of cardiac transplantation to the date of documented Aspergillus infection for each case, or for an equivalent number of days for each control. Univariate and multivariate logistic regressions were used to identify independent predictors of IA in Cohort 1. After 2009, targeted antifungal prophylaxis with oral voriconazole was initiated in patients with risk factors for IA. The incidence of IA was compared pre- and postintervention. Results: IA was identified in 23 of 189 (8.0%) patients within Cohort 1. Significant risk factors for IA on multivariate analysis included an increased number of pretransplant hospitalizations (OR 1.81, 95% CI 1.19-2.76) and posttransplant acute cellular allograft rejection (ACR) (OR 1.99, 95% 1.06-3.75). Following the implementation of targeted antifungal prophylaxis in 2009, IA was identified in 2 of 107 (2.0%) patients in Cohort 2. Conclusions: Increased pretransplant hospitalizations and posttransplant ACR episodes represent significant risk factors for IA following cardiac transplant. Targeted antifungal prophylaxis in at-risk patients reduces the incidence of IA.
引用
收藏
页数:6
相关论文
共 15 条
[1]   Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].
De Pauw, Ben ;
Walsh, Thomas J. ;
Donnelly, J. Peter ;
Stevens, David A. ;
Edwards, John E. ;
Calandra, Thierry ;
Pappas, Peter G. ;
Maertens, Johan ;
Lortholary, Olivier ;
Kauffman, Carol A. ;
Denning, David W. ;
Patterson, Thomas F. ;
Maschmeyer, Georg ;
Bille, Jacques ;
Dismukes, William E. ;
Herbrecht, Raoul ;
Hope, William W. ;
Kibbler, Christopher C. ;
Kullberg, Bart Jan ;
Marr, Kieren A. ;
Munoz, Patricia ;
Odds, Frank C. ;
Perfect, John R. ;
Restrepo, Angela ;
Ruhnke, Markus ;
Segal, Brahm H. ;
Sobel, Jack D. ;
Sorrell, Tania C. ;
Viscoli, Claudio ;
Wingard, John R. ;
Zaoutis, Theoklis ;
Bennett, John E. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821
[2]   Invasive fungal infections in solid organ transplant recipients [J].
Gavalda, J. ;
Meije, Y. ;
Fortun, J. ;
Roilides, E. ;
Saliba, F. ;
Lortholary, O. ;
Munoz, P. ;
Grossi, P. ;
Cuenca-Estrella, M. .
CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 :27-48
[3]   Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study [J].
Gavalda, J ;
Len, O ;
Juan, RS ;
Aguado, JM ;
Fortun, J ;
Lumbreras, C ;
Moreno, A ;
Munoz, P ;
Blanes, M ;
Ramos, A ;
Rufi, G ;
Gurgui, M ;
Torre-Cisneros, J ;
Montejo, M ;
Cuenca-Estrella, M ;
Rodriguez-Tudela, JL ;
Pahissa, A .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (01) :52-59
[4]  
Grossi P, 2000, TRANSPLANTATION, V70, P112
[5]   Invasive aspergillosis in the setting of cardiac transplantation [J].
Montoya, JG ;
Chaparro, SV ;
Celis, D ;
Cortés, JA ;
Leung, AN ;
Robbins, RC ;
Stevens, DA .
CLINICAL INFECTIOUS DISEASES, 2003, 37 :S281-S292
[6]   Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center [J].
Montoya, JG ;
Giraldo, LF ;
Efron, B ;
Stinson, EB ;
Gamberg, P ;
Hung, S ;
Giannetti, N ;
Miller, J ;
Remington, JS .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (05) :629-640
[7]   Risk factors of invasive aspergillosis after heart transplantation:: Protective role of oral itraconazole prophylaxis [J].
Muñoz, P ;
Rodríguez, C ;
Bouza, E ;
Palomo, J ;
Yañez, JF ;
Domínguez, MJ ;
Desco, M .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (04) :636-643
[8]   Invasive aspergillosis among heart transplant recipients: A 24-year perspective [J].
Munoz, Patricia ;
Ceron, Ines ;
Valerio, Maricela ;
Palomo, Jesus ;
Villa, Adolfo ;
Eworo, Alia ;
Fernandez-Yanez, Juan ;
Guinea, Jesus ;
Bouza, Emilio .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (03) :278-288
[9]   Targeted Antifungal Prophylaxis in Heart Transplant Recipients [J].
Munoz, Patricia ;
Valerio, Maricela ;
Palomo, Jesus ;
Giannella, Maddalena ;
Yanez, Juan F. ;
Desco, Manuel ;
Bouza, Emilio .
TRANSPLANTATION, 2013, 96 (07) :664-669
[10]   Efficacy and Tolerance of Different Types of Prophylaxis for Prevention of Early Aspergillosis After Heart Transplantation [J].
Paniagua Martin, M. J. ;
Marzoa Rivas, R. ;
Barge Caballero, E. ;
Grille Cancela, Z. ;
Fernandez, C. J. ;
Solla, M. ;
Pedrosa, V. ;
Rodriguez Fernandez, J. A. ;
Herrera, J. M. ;
Castro-Beiras, A. ;
Crespo-Leiro, M. G. .
TRANSPLANTATION PROCEEDINGS, 2010, 42 (08) :3014-3016